Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Calls and Puts for Income -- Ignore unavailable to you. Want to Upgrade?

To: Carl Worth who wrote (271)	4/22/2007 6:02:26 AM
From: Robohogs	Respond to of 5891

Carl, I actually agree with most of what you wrote - it is pure speculation. I apologize if I came across as advocating a gamble here - I am a bit of a gambling man and even I will not touch this situation. It is too much of a political gamble as both I and the article you linked noted. And yes, frequently stocks peak right at approval and then go down or nowhere. I strongly believe even if DNDN gets approval, the drug will not meet the high expectations of the hopeful and the stock would get hurt. Plus, they will do a capital raise right after either decision which will further pressure the price. One of the earlier posters commented that this was a good company and owning it at a net 8 might not be so bad. I was trying to point out that that is not so. I will say that Forbes article was a bit slanted with a negative bias, but that is the bias of much of the institutional crowd, and a likely reason approval won't mean use. Jon